These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29358902)

  • 1. Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.
    Ferré S; Quiroz C; Guitart X; Rea W; Seyedian A; Moreno E; Casadó-Anguera V; Díaz-Ríos M; Casadó V; Clemens S; Allen RP; Earley CJ; García-Borreguero D
    Front Neurosci; 2017; 11():722. PubMed ID: 29358902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport.
    Ferré S; Quiroz C; Rea W; Guitart X; García-Borreguero D
    Adv Pharmacol; 2019; 84():3-19. PubMed ID: 31229176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.
    Quiroz C; Gulyani S; Ruiqian W; Bonaventura J; Cutler R; Pearson V; Allen RP; Earley CJ; Mattson MP; Ferré S
    Neuropharmacology; 2016 Dec; 111():160-168. PubMed ID: 27600688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal Terminals: Implications for Restless Legs Syndrome.
    Rodrigues MS; Ferreira SG; Quiroz C; Earley CJ; García-Borreguero D; Cunha RA; Ciruela F; Köfalvi A; Ferré S
    Molecules; 2022 Feb; 27(5):. PubMed ID: 35268590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting hypersensitive corticostriatal terminals in restless legs syndrome.
    Yepes G; Guitart X; Rea W; Newman AH; Allen RP; Earley CJ; Quiroz C; Ferré S
    Ann Neurol; 2017 Dec; 82(6):951-960. PubMed ID: 29171915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis.
    Garcia-Borreguero D; Guitart X; Garcia Malo C; Cano-Pumarega I; Granizo JJ; Ferré S
    Sleep Med; 2018 May; 45():94-97. PubMed ID: 29680437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA.
    Lanza G; Ferri R
    Adv Pharmacol; 2019; 84():101-119. PubMed ID: 31229167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Insights into the Neurobiology of Restless Legs Syndrome.
    Ferré S; García-Borreguero D; Allen RP; Earley CJ
    Neuroscientist; 2019 Apr; 25(2):113-125. PubMed ID: 30047288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
    Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
    Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum.
    Ferré S; Sarasola LI; Quiroz C; Ciruela F
    Neuropharmacology; 2023 Feb; 223():109329. PubMed ID: 36375695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine Release in Nucleus Accumbens Is under Tonic Inhibition by Adenosine A
    Roberts BM; Lambert E; Livesey JA; Wu Z; Li Y; Cragg SJ
    J Neurosci; 2022 Mar; 42(9):1738-1751. PubMed ID: 35042768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.
    Earley CJ; Uhl GR; Clemens S; Ferré S
    Sleep Med; 2017 Mar; 31():71-77. PubMed ID: 27539027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep.
    Michaud M; Soucy JP; Chabli A; Lavigne G; Montplaisir J
    J Neurol; 2002 Feb; 249(2):164-70. PubMed ID: 11985381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restless legs and periodic leg movements in sleep syndromes.
    Wetter TC; Pollmächer T
    J Neurol; 1997 Apr; 244(4 Suppl 1):S37-45. PubMed ID: 9112588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep.
    Tribl GG; Asenbaum S; Happe S; Bonelli RM; Zeitlhofer J; Auff E
    Nucl Med Commun; 2004 Jan; 25(1):55-60. PubMed ID: 15061265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathophysiology of restless legs syndrome].
    Miyamoto M; Miyamoto T; Iwanami M; Suzuki K; Hirata K
    Brain Nerve; 2009 May; 61(5):523-32. PubMed ID: 19514512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox.
    Ferré S; Guitart X; Quiroz C; Rea W; García-Malo C; Garcia-Borreguero D; Allen RP; Earley CJ
    Sleep Med Clin; 2021 Jun; 16(2):249-267. PubMed ID: 33985651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep.
    Santamaria J; Iranzo A; Tolosa E
    Sleep Med; 2003 Mar; 4(2):153-5. PubMed ID: 14592347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heterotetrameric structure of the adenosine A
    Cortés A; Casadó-Anguera V; Moreno E; Casadó V
    Adv Pharmacol; 2019; 84():37-78. PubMed ID: 31229177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.
    Happe S; Sauter C; Klösch G; Saletu B; Zeitlhofer J
    Neuropsychobiology; 2003; 48(2):82-6. PubMed ID: 14504416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.